The relationship between the expression of Ki-67 and the prognosis of osteosarcoma.
Antigens, Neoplasm
/ analysis
Bone Neoplasms
/ genetics
Datasets as Topic
Disease-Free Survival
Gene Expression Regulation, Neoplastic
Humans
Kaplan-Meier Estimate
Ki-67 Antigen
/ analysis
Neoplasm Metastasis
Neoplasm Staging
Osteosarcoma
/ genetics
Prognosis
Publication Bias
Sarcoma
/ genetics
Up-Regulation
Clinicopathological features
Ki-67
Meta-analysis
Osteosarcoma
Prognosis
TCGA dataset
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
01 Mar 2021
01 Mar 2021
Historique:
received:
14
12
2020
accepted:
04
02
2021
entrez:
2
3
2021
pubmed:
3
3
2021
medline:
1
5
2021
Statut:
epublish
Résumé
A number of studies have linked positive Ki-67 expression with the prognosis of osteosarcoma (OS) patients. However, the results have been conflicting. To address this controversy, we conducted an analysis using a meta-analysis and a TCGA dataset to estimate the value of Ki-67 expression in the prognosis of OS. A comprehensive search for relevant papers was conducted using NCBI PubMed, Embase, Springer, ISI Web of Knowledge, the Cochrane Library, and CNKI regardless of the publication year. The associations between Ki-67 expression and the clinical features and main prognostic outcomes of OS were measured. The TCGA dataset was also analyzed. The pooled odds ratio (OR) and its 95% confidential intervals (CIs) were utilized for statistical analysis. Overall, a total of 12 studies with 500 cases were included, and the results indicated that the expression of Ki-67 was significantly associated with Enneking stage (OR = 6.88, 95% CI: 2.92-16.22, p < 0.05), distant metastasis (OR = 3.04, 95% CI: 1.51-6.12, p < 0.05) and overall survival (OR = 8.82, 95% CI: 4.68-16.65, p < 0.05) in OS patients. Additionally, we observed no significant heterogeneity among all retrieved studies. Associations between Ki-67 expression and overall survival and disease-free survival of sarcoma were confirmed using the TCGA and Kaplan-Meier plotter datasets. The present study strongly suggests that positive Ki-67 expression was associated with Enneking stage, distant metastasis, and overall survival of OS, and it may be used as a potential biomarker to predict prognosis and guide clinical therapy for OS.
Sections du résumé
BACKGROUND
BACKGROUND
A number of studies have linked positive Ki-67 expression with the prognosis of osteosarcoma (OS) patients. However, the results have been conflicting. To address this controversy, we conducted an analysis using a meta-analysis and a TCGA dataset to estimate the value of Ki-67 expression in the prognosis of OS.
METHODS
METHODS
A comprehensive search for relevant papers was conducted using NCBI PubMed, Embase, Springer, ISI Web of Knowledge, the Cochrane Library, and CNKI regardless of the publication year. The associations between Ki-67 expression and the clinical features and main prognostic outcomes of OS were measured. The TCGA dataset was also analyzed. The pooled odds ratio (OR) and its 95% confidential intervals (CIs) were utilized for statistical analysis.
RESULTS
RESULTS
Overall, a total of 12 studies with 500 cases were included, and the results indicated that the expression of Ki-67 was significantly associated with Enneking stage (OR = 6.88, 95% CI: 2.92-16.22, p < 0.05), distant metastasis (OR = 3.04, 95% CI: 1.51-6.12, p < 0.05) and overall survival (OR = 8.82, 95% CI: 4.68-16.65, p < 0.05) in OS patients. Additionally, we observed no significant heterogeneity among all retrieved studies. Associations between Ki-67 expression and overall survival and disease-free survival of sarcoma were confirmed using the TCGA and Kaplan-Meier plotter datasets.
CONCLUSION
CONCLUSIONS
The present study strongly suggests that positive Ki-67 expression was associated with Enneking stage, distant metastasis, and overall survival of OS, and it may be used as a potential biomarker to predict prognosis and guide clinical therapy for OS.
Identifiants
pubmed: 33648449
doi: 10.1186/s12885-021-07880-y
pii: 10.1186/s12885-021-07880-y
pmc: PMC7923819
doi:
Substances chimiques
Antigens, Neoplasm
0
Ki-67 Antigen
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
210Subventions
Organisme : Central South University
ID : 2018zzts930 & GCX20190879Y
Références
Ann Oncol. 2010 Oct;21 Suppl 7:vii320-5
pubmed: 20943636
Med Oncol. 2013;30(3):624
pubmed: 23749307
Cancer. 2009 Apr 1;115(7):1531-43
pubmed: 19197972
Nat Rev Cancer. 2014 Nov;14(11):722-35
pubmed: 25319867
Clin Exp Med. 2020 May;20(2):261-267
pubmed: 32048073
J Clin Oncol. 2018 Jan 10;36(2):188-193
pubmed: 29220289
J Orthop Surg Res. 2019 Sep 4;14(1):296
pubmed: 31484533
Cancer Treat Res. 2014;162:65-92
pubmed: 25070231
Int J Cancer. 2009 Jul 1;125(1):229-34
pubmed: 19330840
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
J Natl Cancer Inst. 1959 Apr;22(4):719-48
pubmed: 13655060
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Jpn J Clin Oncol. 2011 Apr;41(4):555-64
pubmed: 21233104
Cell Prolif. 1996 Jan;29(1):1-12
pubmed: 8603106
Crit Rev Oncog. 2015;20(3-4):173-97
pubmed: 26349415
J Microsc Ultrastruct. 2019 Nov 08;8(1):20-24
pubmed: 32166060
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Oncotarget. 2017 May 16;8(20):33375-33392
pubmed: 28380419
BMJ Open. 2018 Apr 17;8(4):e019635
pubmed: 29666128
J Immunol. 1984 Oct;133(4):1710-5
pubmed: 6206131
Virchows Arch. 2018 Mar;472(3):341-349
pubmed: 29134440
Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1770-7
pubmed: 21724855
N Am J Med Sci. 2016 May;8(5):210-4
pubmed: 27298815
Oral Oncol. 2003 Jul;39(5):521-30
pubmed: 12747978
Acta Orthop Belg. 2016 Dec;82(4):690-698
pubmed: 29182106
J BUON. 2014 Apr-Jun;19(2):512-6
pubmed: 24965414
Pediatr Blood Cancer. 2016 Jun;63(6):1006-11
pubmed: 26929018
J Orthop Res. 2020 Nov;38(11):2362-2372
pubmed: 32902907
World J Surg. 2013 Aug;37(8):1973-80
pubmed: 23564214
Nat Genet. 2015 Jun;47(6):615-24
pubmed: 25961939
Curr Opin Oncol. 2013 Jul;25(4):398-406
pubmed: 23666471
Nat Rev Endocrinol. 2017 Aug;13(8):480-491
pubmed: 28338660
J Clin Oncol. 2005 Jan 20;23(3):559-68
pubmed: 15659502
Cancer. 1995 Feb 1;75(3):806-14
pubmed: 7828130
J Clin Oncol. 1992 Jan;10(1):5-15
pubmed: 1370176
Hum Pathol. 2002 Feb;33(2):170-4
pubmed: 11957141
Mol Med Rep. 2015 Mar;11(3):1566-72
pubmed: 25384676
Ai Zheng. 2002 Jul;21(7):745-50
pubmed: 12479099
J Clin Oncol. 2003 Apr 15;21(8):1574-80
pubmed: 12697883
J Musculoskelet Neuronal Interact. 2002 Dec;2(6):549-51
pubmed: 15758391
Cancer Epidemiol. 2015 Aug;39(4):593-9
pubmed: 26002013
Arch Pathol Lab Med. 2020 Jan;144(1):15-17
pubmed: 31389716